1. MacDonald AW, Schulz SC: What we know: findings that every theory of schizophrenia should explain. Schizophr Bull . 2009;35(3):493-508. doi:10.1093/schbul/sbp017.
2. McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev . 2008;30:67-76. doi:10.1093/epirev/mxn001.
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM–5 . 5th ed. Washington, DC: American Psychiatric Association; 2013.
4. Palmer BA, Pankratz VS, Bostwick JM. The lifetime risk of suicide in schizophrenia: a reexamination. Arch Gen Psychiatry . 2005;62(3):247-253.
5. American College of Emergency Physicians. Psychiatric and substance abuse survey 2008. http://newsroom.acep.org/download/ACEP%2BPsychiatric%2Band%2BSubstance%2BAbuse%2BSurvey%2B-%2BApril%2B2008.pdf . Accessed October 7, 2018.
6. Pasic J, Russo J, Roy-Byrne P. High utilizers of psychiatric emergency services. Psychiatr Serv . 2005;56(6):678-684.
7. American Hospital Association. AHA annual survery database. http://www.ahadata.com/aha-annual-survey-database-asdb/ . Accessed October 7, 2018.
8. Testa A, Giannuzzi R, Daini S, Bernardini L, Petrongolo L, Gentiloni Silveri N. Psychiatric emergencies (part III): psychiatric symptoms resulting from organic diseases. Eur Rev Med Pharmacol Sci . 2013;17 Suppl 1:86-99.
9. Zun LS. Evidence-based evaluation of psychiatric patient. J Emerg Med . 2005;28(3):277-283.
10. Bryan CA, Mistovich JJ, Krost WS, Limmer DD. In two minds? EMS care of the schizophrenic patient. Recognizing the signs and symptoms of schizophrenia is key to prehospital care. EMS Mag . 2009;38(12):63-71.
11. Lukens TW, Wolf SJ, Edlow JA, et al; American College of Emergency Physicians Clinical Policies Subcommittee (Writing Committee) on Critical Issues in the Diagnosis and Management of the Adult Psychiatric Patient in the Emergency Department. Clinical policy: critical issues in the diagnosis and management of the adult psychiatric patient in the emergency department. Ann Emerg Med . 2006;47(1):79-99.
12. Crump C, Winkleby MA, Sundquist K, Sundquist J. Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study. Am J Psychiatry . 2013;170(3):324-33. doi:10.1176/appi.ajp.2012.12050599.
13. Kroll DS, Smallwood J, Chang G. Drug screens for psychiatric patients in the emergency department: evaluation and recommendations. Psychosomatics . 2013;54(1):60-66. doi:10.1016/j.psym.2012.08.007.
14. Verma S, Chan LL, Chee KS, et al; MOH Clinical Practice Guidelines Workgroup on Schizophrenia. Ministry of Health clinical practice guidelines: schizophrenia. Singapore Med J . 2011;52(7):521-525.
15. Fochtman LJ. Psychiatric perspectives on medical screening of psychiatric patients. Acad Emerg Med . 2002;9(9):963-964.
16. Tijdink JK, van den Heuvel J, Vasbinder EC, can de Ven PM, Honig A. Does on-site urine toxicology screening have an added diagnostic value in psychiatric referrals in an emergency setting? Gen Hosp Psychiatry . 2011;33(6):626-630. doi:10.1016/j.genhosppsych.2011.07.008.
17. Janiak BD, Atteberry S. Medical clearance of the psychiatric patient in the emergency department. J Emerg Med . 2012;43(5):866-870. doi:10.1016/j.jemermed.2009.10.026.
18. Lehman AF, Lieberman JA, Dixon LB, et al; American Psychiatric Association; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry . 2004;161(2 Suppl):1-56.
19. National Institute for Health and Care Excellence. Psychosis and schizophrenia in adults: prevention and management. https://www.nice.org.uk/guidance/cg178 . Published February 2014. Accessed September 25, 2018.
20. Scottish Intercollegiate Guidelines Network. SIGN 131: Management of schizophrenia. https://www.sign.ac.uk/assets/sign131.pdf . Published March 2013. Accessed September 25, 2018. 15.
21. Tucci V, Siever K, Matorin A, Moukaddam N. Down the rabbit hole: emergency department medical clearance of patients with psychiatric or behavioral emergencies. Emerg Med Clin North Am . 2015;33(4):721-737. doi:10.1016/j.emc.2015.07.002.
22. Tandon R, Belmaker RH, Gattaz WF, et al; Section of Pharmacopsychiatry, World Psychiatric Association. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res . 2008;100(1-3):20-38. doi:10.1016/j.schres.2007.11.033.
23. Leucht S, Arbter D, Engel RR, Kissling W, Davis JM. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry . 2009;14(4):429-447. doi:10.1038/sj.mp.4002136.
24. Robinson DG, Woerner MG, Delman HM, Kane JM. Pharmacological treatments for first-episode schizophrenia. Schizophr Bull . 2005;31(3):705-722.
25. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet . 2009;373(9657):31-41. doi:10.1016/S0140-6736(08)61764-X.
26. Komossa K, Rummel-Kluge C, Hunger H, et al. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev . 2010;3:CD006654. doi:10.1002/14651858.CD006654.pub2.
27. Komossa K, Rummel-Kluge C, Hunger H, et al. Amisulpride versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev . 2010;1:CD006624. doi:10.1002/14651858.CD006624.pub2.
28. Komossa K, Rummel-Kluge C, Hunger H, et al. Ziprasidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev . 2009;4:CD006627. doi:10.1002/14651858.CD006627.pub2.
29. Komossa K, Rummel-Kluge C, Schmid F, et al. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev . 2009;4:CD006569. doi:10.1002/14651858.CD006569.pub3.
30. Komossa K, Rummel-Kluge C, Schmid F, et al. Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev . 2010;1:CD006625. doi:10.1002/14651858.CD006625.pub2.
31. Crossley NA, Constante M, McGuire P, Power P. Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: meta-analysis. Br J Psychiatry . 2010;196(6):434-439. doi:10.1192/bjp.bp.109.066217.
32. Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry . 2008;21(2):151-156. doi:10.1097/YCO.0b013e3282f53132.
" class="smart-paging drupal-content" alt="<--pagebreak-->" src="/sites/all/modules/contrib/smart_paging/plugins/wysiwyg/smart_paging/images/spacer.gif">
33. Emsley R, Rabinowitz J, Medori R. Time course for antipsychotic treatment response in first-episode schizophrenia. Am J Psychiatry . 2006;163(4):743-745.
34. Barnes TR; Schizophrenia Consensus Group of British Association for Psychopharmacology. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol . 2011;25(5):567-620. doi:10.1177/0269881110391123.
35. MacEwan JP, Kamat SA, Duffy RA, et al. Hospital readmission rates among patients with schizophrenia treated with long-acting injectables or oral antipsychotics. Psychiatr Serv . 2016;67(11):1183-1188.
36. Patel MX, Taylor M, David AS. Antipsychotic long-acting injections: mind the gap. Br J Psychiatry . 2009;52:S1-S4. doi:10.1192/bjp.195.52.s1.
37. Uchida H, Suzuki T, Takeuchi H, Arenovich T, Mamo DC. Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia: meta-analysis. Schizophr Bull . 2011;37(4):788-799. doi:10.1093/schbul/sbp149.
38. Swartz MS, Stroup TS, McEvoy JP, et al. What CATIE found: results from the schizophrenia trial. Psychiatr Serv . 2008;59(5):500-506. doi:10.1176/ps.2008.59.5.500.
39. Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry . 2006;63(10):1079-1087.
40. Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry . 2001;158(4):518-526.
41. McEvoy JP, Lieberman JA, Stroup TS, et al; CATIE Investigators. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry . 2006;163(4):600-610.
42. Centorrino F, Goren JL, Hennen J, Salvatore P, Kelleher JP, Baldessarini RJ. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits. Am J Psychiatry . 2004;161(4):700-706.
43. Stahl SM, Grady MM. A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. Curr Med Chem . 2004;11(3):313-327.
44. Turkington D, Sensky T, Scott J, et al. A randomized controlled trial of cognitive-behavior therapy for persistent symptoms in schizophrenia: a five-year follow-up. Schizophr Res . 2008;98(1-3):1-7.
45. Malik N, Kingdon D, Pelton J, Mehta R, Turkington D. Effectiveness of brief cognitive-behavioral therapy for schizophrenia delivered by mental health nurses: relapse and recovery at 24 months. J Clin Psychiatry . 2009;70(2):201-207.
46. Haddock G, Barrowclough C, Shaw JJ, Dunn G, Novaco RW, Tarrier N. Cognitive-behavioural therapy v. social activity therapy for people with psychosis and a history of violence: randomised controlled trial. Br J Psychiatry . 2009;194(2):152-157. doi:10.1192/bjp.bp.107.039859.
47. Lysaker PH, Davis LW, Bryson GJ, Bell MD. Effects of cognitive behavioral therapy on work outcomes in vocational rehabilitation for participants with schizophrenia spectrum disorders. Schizophr Res . 2009;107(2-3):186-191. doi:10.1016/j.schres.2008.10.018.
48. Grant PM, Huh GA, Perivoliotis D, Stolar NM, Beck AT. Randomized trial to evaluate the efficacy of cognitive therapy for low-functioning patients with schizophrenia. Arch Gen Psychiatry . 2012;69(2):121-127. doi:10.1001/archgenpsychiatry.2011.129.
49. Girón M, Fernández-Yañez A, Mañá-Alvarenga S, Molina-Habas A, Nolasco A, Gómez-Beneyto M. Efficacy and effectiveness of individual family intervention on social and clinical functioning and family burden in severe schizophrenia: a 2-year randomized controlled study. Psychol Med . 2010;40(1):73-84. doi:10.1017/S0033291709006126.
50. Bressi C, Manenti S, Frongia P, Porcellana M, Invernizzi G. Systemic family therapy in schizophrenia: a randomized clinical trial of effectiveness. Psychother Psychosom . 2008;77(1):43-49.
51. Chien WT, Lee IY. The schizophrenia care management program for family caregivers of Chinese patients with schizophrenia. Psychiatr Serv . 2010;61(3):317-320. doi:10.1176/ps.2010.61.3.317.
52. Sneed J, Balestri M, Belfi BJ. The use of dialectical behavior therapy strategies in the psychiatric emergency room. Psychotherapy Theory, Research & Practice . 2003;40(4):265-277.
53. Murphy SM, Irving CB, Adams CE, Wagar M. Crisis intervention for people with severe mental illnesses. Cochrane Database Syst Rev . 2015;12:CD001087. doi:10.1002/14651858.CD001087.pub5.
54. Mulvey EP. Assessing the evidence of a link between mental illness and violence. Hosp Community Psychiatry . 1994;45(7):663-668.
55. Hiroeh U, Appleby L, Mortensen PB, Dunn G. Death by homicide, suicide, and other unnatural causes in people with mental illness: a population-based study. Lancet . 2001;358(9299):2110-2112.
56. Van Dorn R, Volavka J, Johnson N. Mental disorder and violence: is there a relationship beyond substance use? Soc Psychiatry Psychiatr Epidemiol . 2012;47(3):487-503. doi:10.1007/s00127-011-0356-x.
57. Fazel S, Wolf A, Palm C, Lichtenstein P. Violent crime, suicide, and premature mortality in patients with schizophrenia and related disorders: a 38-year total population study in Sweden. Lancet Psychiatry . 2014;1(1):44-54.
58. National Institute for Health and Care Excellence. Violence and aggression: short-term management in mental health, health and community settings. https://www.nice.org.uk/guidance/ng10/chapter/About-this-guideline . Published May 2015. Accessed September 24, 2018.
59. Wilson MP, Pepper D, Currier GW, Holloman GH Jr, Feifel D. The psychopharmacology of agitation: consensus statement of the american association for emergency psychiatry project Beta psychopharmacology workgroup. West J Emerg Med . 2012;13(1):26-34. doi:10.5811/westjem.2011.9.6866.
60. Tiihonen J, Miitendorfer-Rutz E, Torniainen M, Alexanderson K, Tanskanen A. Mortality and cumulative exposure to antipsychotics, antidepressants, and benzodiazepines in patients with schizophrenia: an observational follow-up study. Am J Psychiatry . 2016;173(6):600-606. doi:10.1176/appi.ajp.2015.15050618.
61. Lambert M, Conus P, Eide P, et al. Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence. Eur Psychiatry . 2004;19(7):415-422.
62. Allen MH, Currier GW, Carpenter D, Ross RW, Doherty JP; Expert Consensus Panel for Behavioral Emergencies 2005. The expert consensus guideline series. Treatment of behavioral emergencies 2005. J Psychiatr Pract . 2005;11 Suppl 1:5-108.
63. Leucht S, Heres S, Kissling W, Davis JM. Evidence based pharmacotherapy of schizophrenia. Int J Neuropsychopharmacol . 2011;14(2):269-284. doi:10.1017/S1461145710001380.
64. Belgamwar RB, Fenton M. Olanzapine IM or velotab for acutely disturbed/agitated people with suspected serious mental illnesses. Cochrane Database Syst Rev . 2005;2:CD003729.
" class="smart-paging drupal-content" alt="<--pagebreak-->" src="/sites/all/modules/contrib/smart_paging/plugins/wysiwyg/smart_paging/images/spacer.gif">
65. Ahmed U, Jones H, Adams CE. Chlorpromazine for psychosis induced aggression or agitation. Cochrane Database Syst Rev . 2010;4:CD007445. doi:10.1002/14651858.CD007445.pub2.
66. US Food and Drug Administration. Drug approval package. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022549_adasuve_toc.cfm. Accessed September 28, 2018.
67. Salmoiraghi A, Hussain S. A systematic review of the use of telepsychiatry in acute settings. J Psychiatr Pract . 2015;21(5):389-393. doi:10.1097/PRA.0000000000000103.
68. Shore JH, Hilty DM, Yellowlees P. Emergency management guidelines for telepsychiatry. Gen Hosp Psychiatry . 2007;29(3):199-206.
69. Seidel RW, Kilqus MD. Agreement between telepsychiatry assessment and face-to-face assessment for emergency department psychiatry patients. J Telemed Telecare . 2014;20(2):59-62. doi:10.1177/1357633X13519902.
70. DeVido J, Glezer A, Branagan L, Lau A, Bourgeois JA. Telepsychiatry for inpatient consultations at a separate campus of an academic medical center. Telemed J E Health . 2016;22(7):572-576. doi:10.1089/tmj.2015.0125.
71. Narasimhan M, Druss BG, Hockenberry JM, et al. Impact of a telepsychiatry program at emergency departments statewide on the quality, utilization, and costs of mental health services. Psychiatr Serv . 2015;66(11):1167-1172. doi:10.1176/appi.ps.201400122.
72. Simon RI, Shuman DW. Clinical issues in psychiatry and the law. In: Hales RE, Yudofsky SC, Roberts LW, eds. The American Psychiatric Publishing Textbook of Psychiatry . 6th ed. Washington, DC: American Psychiatric Publishing; 2014:175-204.
73. Malone D, Newron-Howes G, Simmonds S, Marriot S, Tyrer P. Community mental health teams (CMHTs) for people with severe mental illnesses and disordered personality. Cochrane Database Syst Rev . 2007;3:CD000270.
74. Rosenheck RA, Dennis D. Time-limited assertive community treatment for homeless persons with severe mental illness. Arch Gen Psychiatry . 2001;58(11):1073-1080.
75. Testa A, Giannuzzi R, Sollazzo F, Petrongolo L, Bernardini L, Daini S. Psychiatric emergencies (part I): psychiatric disorders causing organic symptoms. Eur Rev Med Pharmacol Sci . 2013;17 Suppl 1:55-64.